EGFR and cancer: Conversely, no differential benefit with EGFR inhibitors has been observed in Asian patients with EGFR-mutant cancer compared to non-Asians56, which is consistent with a more conserved co-alteration landscape in EGFR-mutant non-Sq NSCLC across ancestries.